what if semaglutide doesn't work Ozempic Is NOT A Weight Loss Drug — Despite Social Media Users Suggest Why Am I Not Losing

The GLP-1 receptor agonist market is growing rapidly, supported by rising obesity and diabetes prevalence, strong clinical outcomes, and increasing patient awareness

Presented for research literature review only Harper S et al

The loss of the chondrocytic phenotype and proliferative potential during in vitro expansion, termed as dedifferentiation, has been well documented

With the Sequence acquisition, the company is positioning itself to support customers who already use semaglutides like Ozempic and Wegovy, and to help get these drugs into the hands of the patient population they were intended for: people managing diabetes and those looking to lose weight as part of a doctor-recommended health plan